JP2020188789A - 免疫療法のためのナノ粒子組成物及び方法 - Google Patents
免疫療法のためのナノ粒子組成物及び方法 Download PDFInfo
- Publication number
- JP2020188789A JP2020188789A JP2020127044A JP2020127044A JP2020188789A JP 2020188789 A JP2020188789 A JP 2020188789A JP 2020127044 A JP2020127044 A JP 2020127044A JP 2020127044 A JP2020127044 A JP 2020127044A JP 2020188789 A JP2020188789 A JP 2020188789A
- Authority
- JP
- Japan
- Prior art keywords
- peg
- aapc
- plga
- pla
- ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 27
- 238000009169 immunotherapy Methods 0.000 title claims abstract description 13
- 239000003446 ligand Substances 0.000 claims abstract description 154
- 239000000427 antigen Substances 0.000 claims abstract description 106
- 108091007433 antigens Proteins 0.000 claims abstract description 104
- 102000036639 antigens Human genes 0.000 claims abstract description 104
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 62
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 58
- 229920000642 polymer Polymers 0.000 claims abstract description 58
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 33
- 229920000747 poly(lactic acid) Polymers 0.000 claims abstract description 21
- 229920001184 polypeptide Polymers 0.000 claims abstract description 11
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 8
- 239000002245 particle Substances 0.000 claims description 143
- 230000027455 binding Effects 0.000 claims description 69
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 108060003951 Immunoglobulin Proteins 0.000 claims description 19
- 102000018358 immunoglobulin Human genes 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 125000000524 functional group Chemical group 0.000 claims description 17
- 210000004602 germ cell Anatomy 0.000 claims description 17
- 230000004927 fusion Effects 0.000 claims description 16
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 13
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 13
- 102000011786 HLA-A Antigens Human genes 0.000 claims description 10
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 9
- 239000000539 dimer Substances 0.000 claims description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 6
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 108020004705 Codon Proteins 0.000 claims description 5
- 101000839781 Homo sapiens Immunoglobulin heavy variable 4-59 Proteins 0.000 claims description 5
- 102100028405 Immunoglobulin heavy variable 4-59 Human genes 0.000 claims description 5
- 150000003141 primary amines Chemical class 0.000 claims description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000001361 intraarterial administration Methods 0.000 claims description 3
- 230000002601 intratumoral effect Effects 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 229930182843 D-Lactic acid Natural products 0.000 claims 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims 1
- 230000005931 immune cell recruitment Effects 0.000 claims 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 16
- 230000020385 T cell costimulation Effects 0.000 abstract description 4
- 230000004913 activation Effects 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 47
- 150000001413 amino acids Chemical group 0.000 description 36
- 229920001223 polyethylene glycol Polymers 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 108091054438 MHC class II family Proteins 0.000 description 20
- 102000043131 MHC class II family Human genes 0.000 description 18
- 239000011324 bead Substances 0.000 description 17
- 108020001507 fusion proteins Proteins 0.000 description 17
- 102000037865 fusion proteins Human genes 0.000 description 17
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 16
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 16
- -1 Melan A / Mart-1 Proteins 0.000 description 14
- 229920001427 mPEG Polymers 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 230000000890 antigenic effect Effects 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108700028369 Alleles Proteins 0.000 description 10
- 102000043129 MHC class I family Human genes 0.000 description 10
- 108091054437 MHC class I family Proteins 0.000 description 10
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 229920001432 poly(L-lactide) Polymers 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 125000003396 thiol group Chemical group [H]S* 0.000 description 6
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000021615 conjugation Effects 0.000 description 4
- 230000000139 costimulatory effect Effects 0.000 description 4
- 239000003431 cross linking reagent Substances 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 3
- 102000009490 IgG Receptors Human genes 0.000 description 3
- 108010073807 IgG Receptors Proteins 0.000 description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000047279 human B2M Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 230000014207 opsonization Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000006152 selective media Substances 0.000 description 3
- 239000012798 spherical particle Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002483 superagonistic effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000008214 Glutamate decarboxylase Human genes 0.000 description 2
- 108091022930 Glutamate decarboxylase Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 206010062639 Herpes dermatitis Diseases 0.000 description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 229920005689 PLLA-PGA Polymers 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102100034091 Receptor-type tyrosine-protein phosphatase-like N Human genes 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 230000007402 cytotoxic response Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 239000002745 poly(ortho ester) Substances 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000012772 sequence design Methods 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002381 testicular Effects 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- BHPSIKROCCEKQR-UHFFFAOYSA-N 3-sulfanylpyrrole-2,5-dione Chemical compound SC1=CC(=O)NC1=O BHPSIKROCCEKQR-UHFFFAOYSA-N 0.000 description 1
- 108010082808 4-1BB Ligand Proteins 0.000 description 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 101150011672 CCL9 gene Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 101710185679 CD276 antigen Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 241000189662 Calla Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100032378 Carboxypeptidase E Human genes 0.000 description 1
- 108010058255 Carboxypeptidase H Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108010044226 Class 8 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000289632 Dasypodidae Species 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100033808 Glycoprotein hormone alpha-2 Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
- 101000930907 Homo sapiens Glucose-6-phosphatase 2 Proteins 0.000 description 1
- 101001069261 Homo sapiens Glycoprotein hormone alpha-2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000591210 Homo sapiens Receptor-type tyrosine-protein phosphatase-like N Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000825079 Homo sapiens Transcription factor SOX-13 Proteins 0.000 description 1
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 101710093458 ICOS ligand Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108050004848 Islet cell autoantigen 1 Proteins 0.000 description 1
- 102100027640 Islet cell autoantigen 1 Human genes 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010051808 Lymphoid tissue hyperplasia Diseases 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102000016200 MART-1 Antigen Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241001306288 Ophrys fuciflora Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001267 Poly(D,L-lactide-co-PPO-co-D,L-lactide) Polymers 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920001283 Polyalkylene terephthalate Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 102100024554 Tetranectin Human genes 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 102100022435 Transcription factor SOX-13 Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- NIGUVXFURDGQKZ-UQTBNESHSA-N alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O NIGUVXFURDGQKZ-UQTBNESHSA-N 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 238000012926 crystallographic analysis Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 201000010255 female reproductive organ cancer Diseases 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 210000000428 immunological synapse Anatomy 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000004514 liver lymphoma Diseases 0.000 description 1
- 201000001037 lung lymphoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008017 ovarian lymphoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 108010055837 phosphocarrier protein HPr Proteins 0.000 description 1
- 229920001245 poly(D,L-lactide-co-caprolactone) Polymers 0.000 description 1
- 229920001253 poly(D,L-lactide-co-caprolactone-co-glycolide) Polymers 0.000 description 1
- 229920000111 poly(butyric acid) Polymers 0.000 description 1
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
- 229920001306 poly(lactide-co-caprolactone) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010066381 preproinsulin Proteins 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 108010013645 tetranectin Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- SBUXRMKDJWEXRL-ZWKOTPCHSA-N trans-body Chemical compound O=C([C@@H]1N(C2=O)[C@H](C3=C(C4=CC=CC=C4N3)C1)CC)N2C1=CC=C(F)C=C1 SBUXRMKDJWEXRL-ZWKOTPCHSA-N 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
本出願は、2014年12月24日出願の米国仮特許出願第62/096,725号に対する優先権を主張するものであり、その全体が参照により本明細書に組み込まれる。
)約150個未満のリガンドまたは約100個未満のリガンドがその表面にコンジュゲートされていて、それによって活性及び/または力価の損失を伴わずに、表面の多量のリガンドによる立体的制約を回避する。
親水性の外装を形成する。粒子は、循環特性、体内分布及び分解速度論を含む薬力学的利点、ならびに抗原特異的T細胞を活性化する高い力価をもたらすように設計される。物理的パラメーターとしては、主にサイズ、表面電荷、ポリマー組成、リガンドコンジュゲートケミストリー、リガンド密度が挙げられる。例えば、いくつかの実施形態では、粒子はPLGAまたはPLAポリマーのコア、及びコポリマーのPEG部分によって形成される親水性シェルを有し、ポリマーの一部はポリペプチドリガンドの末端と結合する。親水性シェルは、リガンドコンジュゲートの官能基に対して不活性である、いくつかのPEG鎖、例えばPLGA−PEG−MeOHまたはPLA−PEG−MeOHポリマーを含む。これらの実施形態では、粒子の化学物質により、リガンド密度の良好な調整が可能である。
LA−ヒト白血球抗原、MHC−主要組織適合遺伝子複合体、VH−可変重鎖、Vκ−可変カッパ軽鎖、及びV領域−抗体の可変領域、VHまたはVκのいずれか。
ように修飾されていてもよい。
mAbのVH鎖及びVL鎖によって形成される抗原結合ループからなる、または本質的にそれからなる一本鎖可変断片(scFv)である。scFv抗体構築物は、短いペプチドリンカーによって頭部−頭部または頭部−尾部の構成で共に結合された、1つまたは複数(2、3、4または5)のVH及びVL超可変領域鎖(3D抗原エピトープ結合ポケットを一緒に形成する各鎖の部分)を含んでいてよい。このような構築物はサイズが小さいため、完全に合成経路によって利便に生成することができる。更に、scFvは免疫原性の可能性を低下させることができる。
いる、合成または組換えのHLAモノマー(例えば、β2ミクログロブリンを有するクラスIアルファ鎖)である。更に、共刺激シグナル(または、他の抗体系のリガンド)は、FabであってもscFvであってもよい。このような実施形態では、2つのシグナルを、目的受容体と結合する抗原結合抗体断片(例えば、scFv)に係留されたHLA分子を含む単一の多機能構築物に組み込むことができる。
面に10〜約80個のコンジュゲートされたリガンド、すなわち粒子当たり10〜約70個、または約10〜約50個のコンジュゲートされたリガンドを含む。
築される。いくつかの実施形態では、捕捉された化合物は、粒子マトリックスの分解により放出される。このようなaAPCによって、オフターゲットの相互作用による不必要な活性を制限することにより、併用療法の許容性と有効性を高めることができ得る。いくつかの実施形態では、ナノ粒子aAPCには、薬物化合物、例えばサイトカイン及び小分子薬が封入されない。
などの、本明細書に記載のHLA抗原提示複合体によって提示されるMART−1、gp100、NY−ESO−1及びMAGE−A3を含む。
を模倣するaAPCの作成が試みられてきたが、本ナノスケールのaAPCは、種々の実施形態において、設計された粒度及び化学物質、T細胞リガンド、リガンド配向、リガンド密度及びリガンド比を有するナノサイズ粒子によって生体系を模倣する。
、または約40nm〜約110nmの範囲内である粒子は、好ましくは上記の平均粒子サイズで、サイズが均一であっても、またはサイズが変化してもよい。いくつかの実施形態では、粒子は、「EPR効果」(Enhanced permeability and
retention effect:血管透過性・滞留性亢進効果)を利用するのに十分に小さい。
は、1〜約100μg、または約1〜約50μg、または粒子1mg当たり1〜約10μg、またはいくつかの実施形態では、粒子1mg当たり2〜6μgであり得る。いくつかの実施形態では、粒子のリガンド密度は、約103〜約105リガンド/μm2または約104リガンド/μm2である。例えば、サイズが20〜200nmの範囲のナノ粒子の場合、ナノ粒子は、平均して粒子当たり約5〜約1500個のリガンド、例えば、粒子当たり約10〜約1500個のリガンド、または粒子当たり約10〜約1200個のリガンド、または粒子当たり約10〜約1000個のリガンド、または粒子当たり約10〜約800個のリガンドを有する。いくつかの実施形態では、粒子は、粒子当たり少なくとも約500個のリガンド、または粒子当たり少なくとも約400個のリガンド、または粒子当たり少なくとも約300個のリガンド、または粒子当たり少なくとも約100個のリガンド、または粒子当たり少なくとも約90個のリガンド、または粒子当たり少なくとも約80個のリガンド、または粒子当たり少なくとも約70個のリガンド、または粒子当たり少なくとも約60個のリガンド、または粒子当たり少なくとも約50個のリガンド、または粒子当たり少なくとも約40個のリガンド、または粒子当たり少なくとも約30個のリガンド、または粒子当たり少なくとも約20個のリガンド、または粒子当たり少なくとも約10個のリガンド、いくつかの実施形態では最小でも粒子当たり約5個のリガンドを含む。
、ポリ(D,L−乳酸−コ−グリコール酸)(PLGA)、ポリ(カプロラクトン)(PCL)、エチレン酢酸ビニルポリマー(EVA)、ポリ(乳酸)(PLA)、ポリ(L−乳酸)(PLLA)、ポリ(グリコール酸)(PGA)、ポリ(L−乳酸−コ−グリコール酸)(PLLGA)、ポリ(D,L−ラクチド)(PDLA)、ポリ(L−ラクチド)(PLLA)、PLGA−b−ポリ(エチレングリコール)−PLGA(PLGA−bPEG−PLGA)、PLLA−bPEG−PLLA、PLGA−PEG−マレイミド(PLGA−PEG−mal)、PLA−PEG−マレイミド、ポリ(D,L−ラクチド−コ−カプロラクトン)、ポリ(D,L−ラクチド−コ−カプロラクトン−コ−グリコリド)、ポリ(D,L−ラクチド−コ−PEO〜コ−D,L−ラクチド)、ポリ(D,L−ラクチド−コ−PPO−コ−D,L−ラクチド)、ポリアルキルシアノアクラレート(cyanoacralate)、ポリウレタン、ポリ−L−リジン(PLL)、ヒドロキシプロピルメタクリレート(HPMA)、ポリエチレングリコール、ポリ−L−グルタミン酸、ポリ(ヒドロキシ酸)、ポリ無水物、ポリオルトエステル、ポリ(エステルアミド)、ポリアミド、ポリ(エステルエーテル)、ポリカーボネート、ポリアルキレン(例えばポリエチレン及びポリプロピレン)、ポリ(エチレングリコール)(PEG)などのポリアルキレングリコール、ポリアルキレンオキシド(PEO)、ポリ(エチレンテレフタレート)のようなポリアルキレンテレフタレート、ポリビニルアルコール(PVA)、ポリビニルエーテル、ポリ(酢酸ビニル)などのポリビニルエステル、ポリ(塩化ビニル)(PVC)などのポリビニルハライド、ポリビニルピロリドン、ポリシロキサン、ポリスチレン(PS)、ポリウレタン、アルキルセルロースなどの誘導体化セルロース、ヒドロキシアルキルセルロース、セルロースエーテル、セルロースエステル、ニトロセルロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロース、アクリル酸のポリマー、例えばポリメチルメタクリレート)(P MA)、
ポリ(エチル(メタ)アクリレート)、ポリ(ブチル(メタ)アクリレート、ポリ(イソブチル(メタ)アクリレート、ポリ(ヘキシル(メタ)アクリレート、ポリ(イソデシル(メタ)アクリレート、ポリ(ラウリル(メタ)アクリレート、ポリ(フェニル(メタ)アクリレート、ポリ(メチルアクリレート)、ポリ(イソプロピルアクリレート)、ポリ(イソブチルアクリレート)、ポリ(オクタデシルアクリレート)(ポリアクリル酸)、及びそれらのコポリマー及び混合物、ポリジオキサノンとそのコポリマー、ポリヒドロキシアルカノエート、ポリプロピレンフマレート)、ポリオキシメチレン、ポロキサマー、ポリ(オルト)エステル、ポリ(酪酸)、ポリ(吉草酸)、ポリ(ラクチド−コ−カプロラクトン)、トリメチレンカーボネート、ポリビニルピロリドン、ポリオルトエステル、ポリホスファゼン及びポリホスホエステル、そのデンドリマー及び誘導体、ならびに2つ以上のこのようなポリマーの混合物及び/またはブロックコポリマーのうち1つ以上を含む。
る。例示的な粒子は、0.3以下の多分散指数(PDI)を有する。いくつかの実施形態では、タンパク質リガンドはそれぞれ、スルフヒドリル−マレイミドの化学作用により粒子と結合される。リガンドは、抗CD28抗体リガンドの集団及びHLAリガンドの集団、ならびにT細胞に提示される1種以上の抗原ペプチドを含む。組成物は、静脈内、動脈内、皮下、皮内、リンパ内、または腫瘍内投与のための薬学的に許容される担体を含む。いくつかの実施形態では、組成物は皮下投与用に製剤化される。
例えばニボルマブ、ペムブロリズマブ及びイピリムマブとともに与えられる。いくつかの実施形態では、付加的療法は、抗CTLA4もしくは抗PD1、または抗PD−L1である。付加的療法またはチェックポイント阻害剤は、その従来的なレジメンに沿って個別に投与しても、または本明細書に記載するナノ粒子への、もしくは別のナノ粒子集団に結合された、追加のリガンドとして投与してもよい。いくつかの実施形態では、初期療法として1種以上の免疫チェックポイント阻害剤を与え、その後、例えば、チェックポイント阻害剤療法の約1〜約8週間後、またはチェックポイント阻害剤療法の約2〜約4週間後に、本明細書に記載するaAPCによる療法を開始する。いくつかの実施形態では、1種以上のチェックポイント阻害剤をナノ粒子療法と同時に与え、例えば、療法の開始時と約2週間毎に、または療法の開始時と1種以上のチェックポイント阻害剤については約2週間毎に、及びナノ粒子療法については約4週間毎に与える。いくつかの実施形態では、患者は、チェックポイント阻害剤療法に対して耐性であるか、または部分的応答もしくは一過性応答のみを示し、本明細書に記載するaAPCは、このような患者における腫瘍退縮を増強する。更に他の実施形態では、通常はチェックポイント阻害剤療法に耐性のある癌に対して、本明細書に記載する組成物は、このような癌へのチェックポイント阻害剤使用の奏功性を高める。
本実施例では、特に、マウス抗CD28抗体のテンプレート由来の生殖細胞系列ヒト化(CDR移植)抗体の配列設計;S241P(Kabat番号付け)ヒンジ安定化突然変異、残存するFcガンマ受容体結合を除去するためのL248E(Kabat番号付け)
突然変異、及び抗体の結合に適したCys残基(S473C、Kabat番号付け)を含有するヒトIgG4を含むヒト定常領域配列の設計;CD28と結合する可能性がない変異体生殖細胞系列ヒト化抗体のVドメインの設計;潜在的なT細胞エピトープを含まない生殖細胞系列ヒト化抗体のN末端にHLA−A*02:01を融合するためのリンカー配列の設計について示す。
2002 169:1119−1125によって選択されたIGHV3/OR16−10よりむしろ)ヒトIGHV4−59生殖細胞系列FWを選択した。軽鎖のテンプレートとしてIGKV4−01生殖細胞系列FWを選択した。このFWはいずれも、それぞれのマウスVH及びVκ配列と62%の相同性を有する。マウスCDRをこれらのFWに移植し、また様々な数のマウスFW残基を加え、3種のヒト化VH変異体及び3種のヒト化Vκ変異体を作製した(図1〜6)。
ヒト化抗CD28抗体のN末端にHLA−A*02:01(IMGTアクセッション番号HLA00005)を融合するリンカーを構築し、潜在的な免疫原性を排除するためにiTope(商標)及びTCED(商標)による分析を取り入れた。
対立遺伝子各々に対して試験したリンカー配列にわたって重複する9量体を用いて実施した。各9量体を、MHCクラスII分子との潜在的な「適合性」及び相互作用に基づいてスコア付けした。ソフトウェアによって算出されるペプチドのスコアは0から1の間である。高い平均結合スコア(iTope(商標)のスコア関数で0.55超)を得た非生殖細胞系列ペプチドが強調表示され、50%以上のMHCクラスII結合ペプチド(すなわち、34個の対立遺伝子のうち17個)が高い結合親和性(スコア0.6超)を有する場合、このようなペプチドを「無差別な高親和性」MHCクラスII結合ペプチドと定義した(これは、CD4+T細胞エピトープを含むため高リスクであると考えられる)。50%以上のMHCクラスII結合ペプチドがスコア0.55超を有する(ただし、0.6超が過半数ではない)ペプチドは、「無差別な中親和性」MHCクラスII結合ペプチドと定義した。配列の更なる分析はTCED(商標)を使用して実施した。先のEpiScreen(商標)試験でT細胞応答を刺激した無関係なタンパク質から、ペプチド(T細胞エピトープ)間の高配列相同性を同定するため、この配列を使用して、BLAST検索によりTCED(商標)を調べた。
GeneOptimizer(登録商標)を使用してコドンを最適化し、最適化した配列を以下に示すようにクローニングして発現させた。
Biacore親和性データ及びその他の考察に基づいて、HC1::LC3及びHC2::LC3の重鎖と軽鎖の組み合わせを、それぞれ第1及び第2のmAb候補として選抜し、StableFast−NS0細胞株を作製した。
CD28に対するヒト化モノクローナル抗体が、mAbをコーティングしたプレート上で、新たに単離したPBMCの増殖を誘導する能力について試験した。図17に示すように、ヒト化抗CD28は親と近似した機能を果たしており、スーパーアゴニストではない。
LA mAbを使用して、ペプチドが負荷されたタンパク質を捕捉し、ELISA法により抗原ペプチド負荷効率を確認する。非特異的ペプチドでは0%(すなわちMHCミスマッチ)であるのに対して、特異的ペプチドでは約90%の再現可能な負荷効率(すなわち正確なMHC制限)が予測される。
以下の実施例は、分子量35KであるPLGA(LA:GA=1:1)から形成されたコアを有するナノ粒子の合成を示す。粒子のコロナは、PLGA−PEG−COOHまたはPLGA−PEG−マレイミドと、PLGA−mPEG(メトキシPEG)の混合物からのPEGコポリマーによって形成する。COOH及びマレイミドの末端官能基により、ポリペプチドのコンジュゲートが可能である。メトキシPEGは、PEG鎖上の末端官能基に対して不活性である。PLGA部分は10〜30K(例えば、約20K)の分子量を有し、PEG部分の分子量は3K及び5Kである。この実施例では、ナノ粒子は、50%のコアPLGA(35K)、及び25%のPLGA−PEG−COOHと25%のPLGA−mPEGとの混合物により形成される。PLGA−PEG−COOH(またはマレイミド)とPLGA−mPEGとの比率によって、粒子表面のリガンド密度の微調整が可能である。例えば類似した分子量及び官能基密度を有する、PLA及びPLA−PEGなどの他のポリマーを使用して類似した粒子を調製することができる。
(例えば、いくつかの実施形態では0.3以下)であり、ゼータ電位(表面電荷)は−15mV〜0mVである。この組成、サイズ及び電荷を有するナノ粒子は、in vivoでのPK/ADMEに有益な特性を有することが予測される。具体的には、腫瘍微小環境を含む標的組織への輸送、ならびに血液とリンパ間の移動が十分可能である程度に小さい(200nm未満)。また、その親水性PEG層及びわずかな負電荷により、血清タンパク質の結合、及び標的組織に分布する前にMPS細胞によって循環から排除される恐れのあるナノ粒子のオプソニン化を遅延させるのに役立つ。このポリマー混合物は、日数で測定される微生物分解速度が2週間程度になるはずである。またタンパク質リガンドが外側に配向されることで、同族のTCR及び共刺激受容体(例えばCD28、4−1BB)とのT細胞の結合と比較して、必然的に最大限の生物学的活性をもたらす。更に、いくつかの実施形態では、製剤化する際、ナノ粒子の疎水性コアに可溶性のペイロード(例えばIL−2、抗TGF−b、IL−21または小分子薬)を充填することができる。
PLGA 35KDa 50% w/w
PLGA−PEG官能基 20KDa〜5KDa 25% w/w
PLGA−PEG−MeOH 20KDa〜5KDa 25% w/w
抗原提示複合体(例えばH2−KbまたはHLA−2)をIgヒンジ領域と直接融合させることによって、二量体の抗原提示リガンドを設計した。H2−KbのFcヒンジタンパク質は、マウスIgG1のヒンジ−CH2−CH3部分に融合されたマウスクラスI Kb細胞外ドメインを含み、不対システイン残基が重鎖231位のセリン残基を置換するように遺伝子操作されている。この設計を図19に示す。
利用可能な一級アミンを介してコンジュゲートされるリガンドとともに、PLGA及びPLGA−PEG−COOHのナノaAPCを調製した。PLGA 40(200nm)を基とするPLGA粒子は、有意な安定性を示さなかった。PLGA−PEG−COOH(40K/3K):PLGA−mPEG(17K/3K)を基とし、1:4のPEG:mPEG比を有する粒子は、良好な安定性及び活性を示した。図20。
粒子をナノ析出法によって調製する。例えば、PLGA−mPEGとPLGA−PEG−マレイミドの混合物(PLGA−PEG−マレイミドの%w/wは1〜55%の間で変化する)をアセトニトリルに溶解して、最終濃度50mg/mLにする。この溶液を、シリンジポンプを使用して5mL/分でPVA溶液(MnPVA=9kDa、0.5%w/v)に撹拌しながら注入する。有機溶媒と水性溶媒の混合比は1:1〜1:20の間で急変させた。マイクロ流体装置、拘束衝突噴流装置及び多重注入口ボルテックスミキサー装置を使用して、優れた均一性と狭い粒度分布を確保した粒子を調製することができる。粒子は、タンジェンシャルフローフィルトレーション(TFF)またはAmicon遠心フィルターを使用して精製する。次に粒子をコンジュゲート緩衝液(HEPES 50mM、EDTA 10mM、pH=6.7)に再懸濁した。最後に、抗CD28及びKbSIY/HLAリガンドの混合物を粒子にコンジュゲートすることにより、ナノaAPCを調製する。リガンドの粒子とのコンジュゲートは、室温で一晩続行する。リガンド:粒子の質量比は、1〜500μg/mg粒子の範囲である。抗CD28:Kb/HLAの比は、0〜1の間で変化する。結合されなかったリガンドはSECまたはTFFを使用して除去する。90nmの平均粒径及び50〜120nmの粒度分布を有する粒子を調製した。図32。
本明細書で言及される特許及び刊行物は全て、その全体が参照により本明細書に組み込まれる。
Claims (44)
- 免疫細胞活性化のためのポリペプチドリガンドを結合させたポリマーナノ粒子を含む人工抗原提示細胞(aAPC)であって、該ナノ粒子が
PLGAまたはPLAポリマーコアと、
PEGポリマー部分がポリペプチドリガンドの末端との結合を有するPEGブラシから形成される親水性シェルとを含む、前記aAPC。 - 前記親水性シェルが、同一のまたは異なる分子量を有するPEGブラシの混合物を更に含む、請求項1に記載のaAPC。
- 前記ポリマーコアが、1:0〜1:1の乳酸:グリコール酸比を基準とする、請求項1または2に記載のaAPC。
- 前記ポリマーコアが、約1:1の乳酸:グリコール酸を有するPLGAである、請求項3に記載のaAPC。
- 前記ポリマーコアがPLAである、請求項3に記載のaAPC。
- 前記コアポリマーが約10K〜約50Kの分子量を有する、請求項1〜5のいずれか1項に記載のaAPC。
- 前記ポリマーナノ粒子が、PLGAもしくはPLAポリマーコア、ならびにPLGA−PEG及び/またはPLA−PEGブロックコポリマーを含み、該PEG部分は親水性シェルを形成する、請求項1〜6のいずれか1項に記載のaAPC。
- 前記ポリペプチドリガンドが、官能基によってPEG末端に結合される、請求項7に記載のaAPC。
- 前記ポリペプチドリガンドが、ポリペプチド上の一級アミンによってPEGと結合される、請求項8に記載のaAPC。
- 前記ポリペプチドリガンドが、不対システイン側鎖によって結合される、請求項8に記載のaAPC。
- 前記PLGA−PEGコポリマーが、約10K〜約50Kの分子量を有するPLGA部分と、約2K〜約10Kの分子量(複数可)を有するPEG部分とを含有する、請求項1〜10のいずれか1項に記載のaAPC。
- 前記PLGAポリマーが約20Kの分子量を有し、前記PEGポリマーが約3K及び/または約5Kの分子量を有する、請求項11に記載のaAPC。
- 前記粒子が、約10K〜約30Kの分子量を有するPLGA部分と、約2K〜約10Kの分子量を有するPEG−MeOH部分とを含有する、PLGA−PEG−MeOHコポリマーを含む、請求項11または12に記載のaAPC。
- 前記PLGA−PEGのPLGA部分が約20Kの分子量を有し、前記PEG−MeOH部分が約3K〜5Kの分子量を有する、請求項13に記載のaAPC。
- 前記PLGA−PEG及びPLGA−PEG−MeOHが、約1:15〜約15:1の
比で存在する、請求項13または14に記載のaAPC。 - 前記PLGA−PEG及びPLGA−PEG−MeOHが、約1:10〜約2:1で存在する、請求項15に記載のaAPC。
- 前記ポリマーが、約50%のPLGA、及び少なくとも約25%のPLGA−PEG−MeOHで存在する、請求項13〜16のいずれか1項に記載のaAPC。
- 前記PLA−PEGコポリマーが、約10K〜約50Kの分子量を有するPLA部分と、約2K〜約10Kの分子量(複数可)を有するPEG部分とを含有する、請求項1〜10のいずれか1項に記載のaAPC。
- 前記PLA−PEGのPLA部分が約20Kの分子量を有し、前記PEG部分が約3K及び/または約5Kの分子量を有する、請求項18に記載のaAPC。
- 前記粒子が、約10K〜約30Kの分子量を有するPLA部分と、約2K〜約10Kの分子量を有するPEG−MeOH部分とを含有する、PLA−PEG−MeOHコポリマーを含む、請求項18または19に記載のaAPC。
- 前記PLA−PEGポリマーのPLA部分が約20Kの分子量を有し、前記PEG−MeOH部分が3K〜5Kの分子量を有する、請求項20に記載のaAPC。
- 前記PLA−PEG及びPLA−PEG−MeOHが、約1:15〜約15:1の比で存在する、請求項20または21に記載のaAPC。
- 前記PLA−PEGとPLA−PEG−MeOHが、約1:10〜約2:1で存在する、請求項22に記載のaAPC。
- 前記ポリマーが、約50%のPLA、及び少なくとも約25%のPLA−PEG−MeOHで存在する、請求項21〜23のいずれか1項に記載のaAPC。
- 前記ナノ粒子が、約20〜200nmの範囲のサイズを有する、請求項1〜24のいずれか1項に記載のaAPC。
- 前記aAPCが、約0〜−20mVの表面電荷を有する、請求項1〜25のいずれか1項に記載のaAPC。
- 前記aAPCが約−5〜約−10mVの表面電荷を有する、請求項26に記載のaAPC。
- 粒子当たり約200個未満のリガンドを有する、請求項1〜27のいずれか1項に記載のaAPC。
- 前記ポリペプチドリガンドが、ペプチド−HLAリガンドと、1つ以上の抗CD28または抗4−1BBリガンドを含む、請求項1〜28のいずれか1項に記載のaAPC。
- 場合により5〜15のマウスフレームワーク残基を有するヒトIGHV4−59生殖細胞系列フレームワークと、場合により3〜15のマウスフレームワーク残基を有するIGKV4−01生殖細胞系列フレームワークとを有する抗CD28抗体リガンドを含む、請求項29に記載のaAPC。
- 前記抗CD28リガンドが、抗原結合抗体断片または部分を含む、請求項30に記載のaAPC。
- 前記抗CD28リガンドがscFvを含む、請求項31に記載のaAPC。
- 前記HLAリガンドが二量体である、請求項29に記載のaAPC。
- 前記HLAがHLA−A*02:01である、請求項33に記載のaAPC。
- 前記HLAが免疫グロブリン配列との融合体を含む、請求項33または34に記載のaAPC。
- 前記抗CD28抗体リガンド及びHLA免疫グロブリン融合体が、S241及びL248に突然変異と、コドン473に不対システインを有するIgG4定常領域を有する、請求項35に記載のaAPC。
- 前記抗CD28抗体リガンドが、免疫グロブリン重鎖のコドン473で不対システインによって粒子とコンジュゲートされる、請求項36に記載のaAPC。
- 前記HLAリガンドが、免疫グロブリン重鎖のコドン473で不対システインによって粒子とコンジュゲートされる、請求項36または37に記載のaAPC。
- 前記HLAリガンドが、免疫グロブリン可変ドメイン配列なしで、免疫グロブリンヒンジ領域に融合されるHLAの細胞外ドメインを含む、請求項35に記載のaAPC。
- 請求項1〜39のいずれか1項に記載のaAPCを含む組成物を患者に投与することを含む、抗原特異的な細胞傷害性T細胞の形成を誘導する方法。
- 前記患者が癌患者である、請求項40に記載の方法。
- 前記患者が、1種以上のチェックポイント阻害剤による療法を受けている、または受けた経験がある、請求項40または41に記載の方法。
- 前記患者がT細胞養子免疫療法を受けている、請求項40または41に記載の方法。
- 前記aAPC組成物を静脈内投与、動脈内投与、皮下投与、皮内投与、リンパ内投与または腫瘍内投与により投与する、請求項40〜43のいずれか1項に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022126697A JP2022166133A (ja) | 2014-12-24 | 2022-08-08 | 免疫療法のためのナノ粒子組成物及び方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462096725P | 2014-12-24 | 2014-12-24 | |
US62/096,725 | 2014-12-24 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017534743A Division JP6743022B2 (ja) | 2014-12-24 | 2015-12-24 | 免疫療法のためのナノ粒子組成物及び方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022126697A Division JP2022166133A (ja) | 2014-12-24 | 2022-08-08 | 免疫療法のためのナノ粒子組成物及び方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020188789A true JP2020188789A (ja) | 2020-11-26 |
JP7127876B2 JP7127876B2 (ja) | 2022-08-30 |
Family
ID=56151617
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017534743A Active JP6743022B2 (ja) | 2014-12-24 | 2015-12-24 | 免疫療法のためのナノ粒子組成物及び方法 |
JP2020127044A Active JP7127876B2 (ja) | 2014-12-24 | 2020-07-28 | 免疫療法のためのナノ粒子組成物及び方法 |
JP2022126697A Pending JP2022166133A (ja) | 2014-12-24 | 2022-08-08 | 免疫療法のためのナノ粒子組成物及び方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017534743A Active JP6743022B2 (ja) | 2014-12-24 | 2015-12-24 | 免疫療法のためのナノ粒子組成物及び方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022126697A Pending JP2022166133A (ja) | 2014-12-24 | 2022-08-08 | 免疫療法のためのナノ粒子組成物及び方法 |
Country Status (14)
Country | Link |
---|---|
US (3) | US10632193B2 (ja) |
EP (2) | EP3970748A1 (ja) |
JP (3) | JP6743022B2 (ja) |
KR (2) | KR20230144092A (ja) |
CN (2) | CN116869964A (ja) |
AU (2) | AU2015371265B2 (ja) |
BR (1) | BR112017013838A2 (ja) |
CA (1) | CA2971419A1 (ja) |
ES (1) | ES2897707T3 (ja) |
HK (1) | HK1245661A1 (ja) |
IL (2) | IL286025B2 (ja) |
MX (2) | MX2017008487A (ja) |
SG (1) | SG11201705064XA (ja) |
WO (1) | WO2016105542A2 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL286053B2 (en) | 2005-10-18 | 2023-03-01 | Nat Jewish Health | A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin |
KR20170078862A (ko) | 2008-05-16 | 2017-07-07 | 타이가 바이오테크놀로지스, 인코포레이티드 | 항체 및 그 제조 방법 |
EP3916010A1 (en) | 2008-08-28 | 2021-12-01 | Taiga Biotechnologies, Inc. | Modulators of myc, methods of using the same and methods of identifying agents that modulate myc |
EP3868387A1 (en) | 2012-07-20 | 2021-08-25 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
CA3029813A1 (en) | 2016-06-13 | 2017-12-21 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
BR112019009477A2 (pt) * | 2016-11-09 | 2019-07-30 | Uti Lp | moléculas de classe ii de pmhc recombinantes |
CN113786476A (zh) * | 2016-12-02 | 2021-12-14 | 泰加生物工艺学公司 | 纳米颗粒调配物 |
US11433131B2 (en) | 2017-05-11 | 2022-09-06 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (SNAs) |
SG11202000425QA (en) * | 2017-07-21 | 2020-02-27 | Berkeley Lights Inc | Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated t cells, and uses thereof |
US11925693B2 (en) | 2017-07-27 | 2024-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Polymeric nanoparticles for enhanced cancer immunotherapy |
US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
EP3678701A4 (en) | 2017-09-05 | 2021-12-01 | Torque Therapeutics, Inc. | THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF |
MX2020003129A (es) * | 2017-09-20 | 2020-10-12 | Neximmune Inc | Composiciones celulares que comprenden linfocitos t específicos para antígenos para una terapia adoptiva. |
CN108359013A (zh) * | 2018-02-07 | 2018-08-03 | 上海交通大学 | 一种人工抗原递呈纳米制剂及其用于体内外扩增特异性t细胞的应用 |
CN110464848B (zh) * | 2018-05-11 | 2022-07-05 | 中国医学科学院肿瘤医院 | 人工抗原递呈细胞及其制备方法与应用 |
KR20210063362A (ko) | 2018-09-21 | 2021-06-01 | 버클리 라잇츠, 인크. | 작용화된 웰 플레이트, 이의 제조 및 사용 방법 |
CN110176272B (zh) * | 2019-04-18 | 2021-05-18 | 浙江工业大学 | 一种基于多序列联配信息的蛋白质二硫键预测方法 |
CN110964816A (zh) * | 2019-11-20 | 2020-04-07 | 深圳市鲲鹏未来科技有限公司 | 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法 |
CN112843016A (zh) * | 2020-12-25 | 2021-05-28 | 浙江康佰裕生物科技有限公司 | 一种人工抗原呈递纳米粒及其制备方法和应用 |
WO2023060123A1 (en) * | 2021-10-05 | 2023-04-13 | The Johns Hopkins University | Mhc ii artificial antigen presenting cells harness the effector and helper functions of antigen-specific cd4+ t cells |
WO2023155844A1 (zh) * | 2022-02-16 | 2023-08-24 | 上海优替济生生物医药有限公司 | 亲和力成熟的抗cd40抗体 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100028450A1 (en) * | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
WO2010042555A2 (en) * | 2008-10-06 | 2010-04-15 | The Brigham And Women's Hospital, Inc. | Particles with multiple functionalized surface domains |
JP2012505249A (ja) * | 2008-10-12 | 2012-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫ナノ治療剤による抗原提示細胞のターゲティング |
US8629098B2 (en) * | 2008-01-15 | 2014-01-14 | Yale University | Compositions and methods for adoptive and active immunotherapy |
WO2014052545A2 (en) * | 2012-09-28 | 2014-04-03 | Dana-Farber Cancer Institute, Inc. | Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis |
WO2014160132A1 (en) * | 2013-03-14 | 2014-10-02 | The Johns Hopkins University | Nanoscale artificial antigen presenting cells |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
JP2763958B2 (ja) | 1990-06-11 | 1998-06-11 | ネクスター ファーマスーティカルズ,インコーポレイテッド | 核酸リガンド |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
WO1996002561A1 (en) | 1994-07-20 | 1996-02-01 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
DE19722888A1 (de) | 1997-05-28 | 1998-12-03 | Thomas Prof Dr Huenig | Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten |
DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
ES2260009T3 (es) | 1999-05-05 | 2006-11-01 | Phylogica Limited | Aislamiento de moduladores biologicos a partir de bancos de fragmentos genicos biodiversos. |
AU4761100A (en) | 1999-05-26 | 2000-12-18 | Kalle Saksela | Methods and materials for generating sh3 domains with tailored binding properties |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
CA2411828A1 (en) | 2000-06-23 | 2002-01-03 | Maxygen, Inc. | Novel co-stimulatory molecules |
DE60140474D1 (de) | 2000-09-08 | 2009-12-24 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
EP2284270A3 (en) | 2000-12-13 | 2012-07-25 | Anaphore, Inc. | Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
US6811785B2 (en) * | 2001-05-07 | 2004-11-02 | Mount Sinai School Of Medicine Of New York University | Multivalent MHC class II—peptide chimeras |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
ES2268074T3 (es) | 2001-09-14 | 2007-03-16 | ROTHMANS, BENSON & HEDGES INC. | Procedimiento de preparacion de materiales microporosos revestidos de oxidos metalicos de tierras raras. |
JP5068931B2 (ja) | 2002-07-12 | 2012-11-07 | ザ ジョンズ ホプキンス ユニバーシティー | 独自のクローン形質のリンパ球受容体に結合する試薬および方法 |
AU2003282724B2 (en) | 2002-10-02 | 2010-03-04 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
DE602004031589D1 (de) | 2003-01-07 | 2011-04-14 | Dyax Corp | Kunitz-domäne-bibliothek |
US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
CA2665568C (en) | 2006-10-04 | 2018-01-09 | Janssen Pharmaceutica, N.V. | Preparation of inactivated artificial antigen presenting cells and their use in cell therapies |
DK2131856T3 (da) | 2007-03-07 | 2014-12-15 | Uti Limited Partnership | Sammensætninger og fremgangsmåder til forebyggelsen og behandlingen af autoimmune tilstande |
RU2549676C2 (ru) | 2007-06-01 | 2015-04-27 | Юниверсити Оф Мэрилэнд, Балтимор | СРЕДСТВА НА ОСНОВЕ КОНСТАНТНОЙ ОБЛАСТИ ИММУНОГЛОБУЛИНА СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР |
PT2195023T (pt) | 2007-08-29 | 2018-06-08 | Sanofi Sa | Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações |
JP6363320B2 (ja) | 2008-06-16 | 2018-07-25 | ファイザー・インク | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
JP2013540701A (ja) | 2010-08-12 | 2013-11-07 | セラクローン サイエンシーズ, インコーポレイテッド | 抗赤血球凝集素抗体組成物およびその使用方法 |
US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
EP2596802A1 (en) * | 2011-11-23 | 2013-05-29 | PLS-Design GmbH | Pharmaceutical composition for treatment of allergic reactions |
JP2015500296A (ja) | 2011-12-09 | 2015-01-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 定義された動的形状を有する人工抗原提示細胞 |
AU2012351994B2 (en) | 2011-12-14 | 2015-11-05 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
US9212224B2 (en) * | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
BR112015032277B1 (pt) * | 2013-06-24 | 2020-12-01 | Neximmune | complexo de apresentação de antígeno, seu uso, e composição |
RU2696876C2 (ru) | 2013-11-04 | 2019-08-07 | Ютиай Лимитед Партнершип | Способы и композиции для устойчивой иммунотерапии |
KR20210032011A (ko) | 2014-09-17 | 2021-03-23 | 더 존스 홉킨스 유니버시티 | 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법 |
-
2015
- 2015-12-24 JP JP2017534743A patent/JP6743022B2/ja active Active
- 2015-12-24 WO PCT/US2015/000340 patent/WO2016105542A2/en active Application Filing
- 2015-12-24 ES ES15873812T patent/ES2897707T3/es active Active
- 2015-12-24 CA CA2971419A patent/CA2971419A1/en active Pending
- 2015-12-24 BR BR112017013838A patent/BR112017013838A2/pt active Search and Examination
- 2015-12-24 KR KR1020237032105A patent/KR20230144092A/ko active Application Filing
- 2015-12-24 CN CN202211687677.8A patent/CN116869964A/zh active Pending
- 2015-12-24 EP EP21190343.0A patent/EP3970748A1/en active Pending
- 2015-12-24 IL IL286025A patent/IL286025B2/en unknown
- 2015-12-24 SG SG11201705064XA patent/SG11201705064XA/en unknown
- 2015-12-24 EP EP15873812.0A patent/EP3237003B1/en active Active
- 2015-12-24 AU AU2015371265A patent/AU2015371265B2/en active Active
- 2015-12-24 MX MX2017008487A patent/MX2017008487A/es unknown
- 2015-12-24 CN CN201580076816.5A patent/CN107427573B/zh active Active
- 2015-12-24 KR KR1020177020448A patent/KR102582035B1/ko active IP Right Grant
- 2015-12-24 US US15/537,773 patent/US10632193B2/en active Active
-
2017
- 2017-06-20 IL IL253036A patent/IL253036B/en unknown
- 2017-06-23 MX MX2022003698A patent/MX2022003698A/es unknown
-
2018
- 2018-04-24 HK HK18105320.0A patent/HK1245661A1/zh unknown
-
2020
- 2020-03-18 US US16/822,167 patent/US11510981B2/en active Active
- 2020-07-28 JP JP2020127044A patent/JP7127876B2/ja active Active
-
2021
- 2021-09-02 AU AU2021225200A patent/AU2021225200A1/en not_active Abandoned
-
2022
- 2022-08-08 JP JP2022126697A patent/JP2022166133A/ja active Pending
- 2022-10-20 US US17/970,238 patent/US20240066120A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100028450A1 (en) * | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
US8629098B2 (en) * | 2008-01-15 | 2014-01-14 | Yale University | Compositions and methods for adoptive and active immunotherapy |
WO2010042555A2 (en) * | 2008-10-06 | 2010-04-15 | The Brigham And Women's Hospital, Inc. | Particles with multiple functionalized surface domains |
JP2012505249A (ja) * | 2008-10-12 | 2012-03-01 | マサチューセッツ インスティテュート オブ テクノロジー | 免疫ナノ治療剤による抗原提示細胞のターゲティング |
WO2014052545A2 (en) * | 2012-09-28 | 2014-04-03 | Dana-Farber Cancer Institute, Inc. | Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis |
WO2014160132A1 (en) * | 2013-03-14 | 2014-10-02 | The Johns Hopkins University | Nanoscale artificial antigen presenting cells |
Non-Patent Citations (2)
Title |
---|
COLLOIDS AND SURFACES B: BIOINTERFACES, 2000, VOL.18, P.301-313, JPN6019046917, ISSN: 0004577578 * |
INDIAN DRUGS, 2012, VOL.49, NO.12, P.5-22, JPN6019046914, ISSN: 0004577577 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7127876B2 (ja) | 免疫療法のためのナノ粒子組成物及び方法 | |
US11712477B2 (en) | Compositions and methods for immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200821 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211029 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220401 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220712 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220810 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7127876 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |